A method for preparing aspirin-nicotinamide eutectic and characterizing it by terahertz spectroscopy

Aspirin-nicotinamide cocrystals were prepared by solvent-free milling, and the problems of aspirin cocrystal preparation and characterization were solved by combining PXRD, THz-TDS and DFT theoretical calculations. This significantly improved the water solubility of aspirin and elucidated the intermolecular interaction mechanism.

CN123106428APending Publication Date: 2026-11-17GUILIN UNIV OF ELECTRONIC TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611430106.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies make it difficult to prepare aspirin cocrystals using simple methods, and it is also difficult to effectively resolve the mechanism of weak intermolecular interactions. Traditional spectroscopic methods are insufficient, and solvent methods are prone to producing residues.

Method used

Aspirin-nicotinamide drug cocrystals were prepared by solvent-free milling. A comprehensive characterization method combining powder X-ray diffraction, terahertz spectroscopy, and theoretical calculations, including PXRD, THz-TDS, and DFT theoretical calculations, was used to analyze the cocrystal phases and intermolecular interactions.

Benefits of technology

The process achieved a 17.6-fold increase in the water solubility of aspirin, with a simple process, no solvent residue, comprehensive and reliable characterization methods, and elucidated the microscopic mechanism of eutectic formation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106428A_ABST
    Figure CN123106428A_ABST
Patent Text Reader

Abstract

This invention discloses an aspirin-nicotinamide drug cocrystal and its preparation and comprehensive characterization method, belonging to the field of pharmaceutical crystal engineering technology. The cocrystal has a 1:1 molar ratio of aspirin to nicotinamide and is prepared using a solvent-free planetary milling process. PXRD and terahertz time-domain spectroscopy reveal unique characteristic peaks distinct from monomers and physical mixtures. Combined with DFT theoretical simulation, IRI qualitative visualization, EDA-FF energy decomposition, and PED vibrational mode assignment, the crystallization mechanism driven by hydrogen bonding and van der Waals forces is elucidated. At 20℃, the cocrystal exhibits a 17.6-fold increase in equivalent aspirin solubility compared to the active pharmaceutical ingredient. This invention's process leaves no solvent residue, and the characterization method can simultaneously confirm the phase composition and analyze the microscopic mechanism, making it suitable for the development of antipyretic and analgesic drug formulations and the study of drug cocrystal mechanisms.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of drug cocrystal preparation and crystal characterization technology, specifically to an aspirin-nicotinamide drug cocrystal and its grinding preparation method, as well as a comprehensive characterization method for the cocrystal combining terahertz time-domain spectroscopy, powder X-ray diffraction, and theoretical calculation. Background Technology

[0002] Aspirin (acetylsalicylic acid, ASA) possesses antipyretic, analgesic, and antithrombotic pharmacological activities and is widely used clinically. However, its poor water solubility limits drug absorption and clinical efficacy. Drug cocrystallization technology can improve the solubility of the active pharmaceutical ingredient by forming non-covalent intermolecular interactions between the cocrystallized precursor molecule and the active drug molecule without altering the active drug structure.

[0003] In current drug cocrystal development, relying solely on powder X-ray diffraction can only determine the formation of a new crystalline phase, but it is difficult to resolve weak interactions such as intermolecular hydrogen bonds and van der Waals forces. Conventional infrared and Raman spectroscopy have weak responses to low-frequency lattice vibrations, making it difficult to reveal the microscopic mechanisms of cocrystal formation. Some cocrystal preparation processes are subject to harsh conditions, and solvent methods are prone to solvent residue. Therefore, there is an urgent need to develop a simple, solvent-free method for preparing aspirin cocrystals, and to establish a complete characterization scheme that includes spectroscopic testing, diffraction characterization, and quantum chemical calculations to identify the cocrystal phase and resolve the mechanisms of weak intermolecular interactions. Summary of the Invention

[0004] (a) Purpose of the invention

[0005] This invention provides an aspirin-nicotinamide drug cocrystal, and discloses its solvent-free grinding preparation method, as well as a comprehensive characterization method combining terahertz-TDS, PXRD, and DFT theoretical calculations. This cocrystal can significantly improve the water solubility of aspirin, the preparation process is simple and controllable, and the characterization methods can simultaneously achieve phase confirmation and qualitative and quantitative analysis of weak intermolecular interactions.

[0006] (II) Technical Solution

[0007] 1. Aspirin-nicotinamide drug cocrystal

[0008] The active pharmaceutical ingredient in the co-crystal is aspirin (ASA), and the co-crystal precursor is nicotinamide (NCT); the molar ratio of aspirin to nicotinamide is 1:1; the co-crystal constructs its lattice through intermolecular hydrogen bonds and weak van der Waals interactions.

[0009] Its powder X-ray diffraction (PXRD) pattern shows characteristic diffraction peaks at 2θ of 9.21°, 13.80°, 17.18°, and 28.74°;

[0010] Its terahertz time-domain spectrum shows characteristic absorption peaks at 0.91 THz, 1.51 THz, and 1.79 THz, which are distinct from those of the monomer and the physical mixture.

[0011] At 20°C, the solubility of eutectic equivalent aspirin is 17.6 times higher than that of pure aspirin.

[0012] 2. Preparation method of aspirin-nicotinamide drug cocrystal

[0013] Includes the following steps:

[0014] (1) Raw material pretreatment: Take aspirin and nicotinamide with a purity ≥98% and weigh them accurately according to a molar ratio of 1:1;

[0015] (2) Premixing: Under a dry glove box environment, manually premix the two powders for 5 minutes;

[0016] (3) Planetary ball mill grinding: grinding speed 300r / min, grinding time 2h, maintaining a low humidity and dry environment throughout the process;

[0017] (4) Product preservation: After grinding, the product is taken out immediately, sealed and stored in a desiccator to obtain aspirin-nicotinamide drug eutectic powder.

[0018] 3. Comprehensive Characterization Methods for Drug Cocrystallization

[0019] It consists of two parts: experimental characterization of the phases and theoretical calculation analysis.

[0020] ①Experimental characterization:

[0021] a) Powder X-ray diffraction (PXRD) test, scanning range 5°-40°, compare with the spectra of monomers and physical mixtures, the appearance of specific diffraction peaks indicates the formation of a new crystal phase;

[0022] b) Terahertz time-domain spectroscopy (THz-TDS) test: collect absorption spectra from 0.4 to 2.0 THz, compare monomers with physical mixtures, and identify the eutectic-specific characteristic absorption peaks;

[0023] ② Theoretical calculation analysis:

[0024] a) Construct an initial 1:1 aspirin-nicotinamide cocrystal unit cell model, and perform geometric optimization and spectral simulation using DFT-D3 / B3LYP-D3 and 6-311G** basis sets;

[0025] b) Qualitative and visual analysis of weak intermolecular interactions is conducted using the IRI interaction region indicator;

[0026] c) Using the EDA-FF energy decomposition method, the interaction energies of electrostatics, dispersion, and repulsion are quantitatively separated to analyze the driving force of eutectic crystal formation.

[0027] d) Combining the PED potential energy distribution decomposition, the vibrational modes of the terahertz characteristic peaks are assigned.

[0028] (III) Implementation Process

[0029] Weigh ASA and NCT powders in a 1:1 molar ratio → premix in a glove box → grind in a planetary ball mill at 300 r / min for 2 h → seal and dry for storage to obtain the target eutectic; conduct PXRD diffraction and terahertz-TDS spectroscopy tests sequentially; establish a eutectic unit cell model, perform DFT geometry optimization and spectral simulation; perform IRI visualization qualitative analysis, EDA-FF energy decomposition quantitative analysis, and PED vibrational mode assignment to complete the confirmation of the eutectic phase and the analysis of the microscopic crystallization mechanism; conduct static equilibrium solubility tests to evaluate the solubility performance.

[0030] (iv) Beneficial effects

[0031] This invention uses a solvent-free planetary milling process to prepare ASA-NCT eutectic, which is simple to operate, leaves no organic solvent residue, and has good process repeatability; the product has an equivalent aspirin solubility that is 17.6 times higher than that of the raw material, effectively improving water solubility.

[0032] Characterization was performed using a combination of PXRD and terahertz-TDS experiments: PXRD confirmed the new crystalline phase; terahertz spectroscopy is sensitive to low-frequency lattice vibrations and can capture the specific characteristic absorption peaks corresponding to weak intermolecular interactions in eutectic molecules, thus compensating for the shortcomings of traditional spectroscopic methods.

[0033] With the support of DFT theoretical simulation, combined with IRI qualitative visualization, EDA-FF energy decomposition quantification, and PED vibrational attribution, it can not only verify experimental spectra, but also resolve weak intermolecular interactions such as hydrogen bonds and van der Waals forces, elucidate the microscopic driving force for cocrystal formation, and provide a complete characterization approach for the cocrystal development of similar drugs.

[0034] All experimental and computational schemes are reproducible, making them suitable for screening drug cocrystal formulations and studying mechanisms. Detailed Implementation

[0035] 1. Example 1: Preparation of Aspirin-Nicotinamide Cocrystal

[0036] Raw materials: Aspirin (CAS: 50-78-2), Nicotinamide (CAS: 98-92-0), purity of both raw materials ≥99%;

[0037] 1) Weigh ASA and NCT powders using an electronic balance (accuracy 0.1 mg) at a molar ratio of 1:1;

[0038] 2) Premix manually for 5 minutes in a dry glove box;

[0039] 3) The planetary ball mill is set to a speed of 300 r / min and a grinding time of 2 hours; the entire process is carried out in a low-humidity environment to prevent aspirin from being hydrolyzed by water;

[0040] 4) After grinding, the powder is immediately transferred to a dryer and sealed container for storage to obtain aspirin-nicotinamide drug eutectic powder.

[0041] 2. Example 2 Sample Control Sample Preparation

[0042] 1) ASA monomers and NCT monomers: directly use commercially available raw materials;

[0043] 2) Physical mixture: ASA and NCT are simply mixed at a molar ratio of 1:1 and ground for a short time of 0.5-1 min. No eutectic reaction occurs. This mixture is used as a reference sample.

[0044] 3. Example 3 Experimental Characterization Test

[0045] 1) PXRD powder diffraction test: Scanning range 5°-40°, Cu target, to obtain sample diffraction pattern; new diffraction peaks appeared in eutectic sample at 9.21°, 13.80°, 17.18°, and 28.74°, which distinguished the monomer and physical mixture, and proved the formation of new crystal phase.

[0046] 2) Terahertz-TDS spectroscopy test, instrument model Z-3 terahertz time-domain spectroscopy system, test band 0.4-2.0THz; the eutectic sample showed three unique characteristic absorption peaks at 0.91THz, 1.51THz and 1.79THz; the physical mixture only showed the superposition of the peaks of the two raw materials, without new characteristic peaks.

[0047] 4. Theoretical Calculation Analysis of Example 4

[0048] 1) Cell modeling: Based on the single crystal parameters in the CCDC database, an initial model of the ASA-NCT (1:1) eutectic cell was constructed;

[0049] 2) Gaussian software, B3LYP-D3 method, 6-311G** basis set, geometry optimization, simulation of theoretical terahertz spectrum;

[0050] 3) Multiwfn software is used to perform IRI interaction region indicator calculations and visualize hydrogen bonding, van der Waals, and steric repulsion interactions;

[0051] 4) EDA-FF energy decomposition separates the total interaction into electrostatic, dispersion, and repulsive components, and quantitatively analyzes the crystallization driving force;

[0052] 5) PED potential energy distribution decomposition, and completion of vibration mode assignment for the characteristic peaks at 0.91THz and 1.51THz;

[0053] The results show that the synergistic effect of intermolecular hydrogen bonds and van der Waals dispersion in the eutectic system drives the formation of the eutectic lattice.

[0054] 5. Solubility Test in Example 5

[0055] Using the static equilibrium method, at 20℃, with a distilled water system and pH 6.0-7.0, the solubility of pure ASA was measured to be 1.78 mg / mL; the solubility of the eutectic equivalent ASA was 31.32 mg / mL, representing an increase in solubility of approximately 17.6 times. Attached Figure Description

[0056] To make the content of this invention easier to understand, the invention will be further described in detail below with reference to specific embodiments and accompanying drawings, wherein...

[0057] Figure 1 This is a schematic diagram of the single-molecule structure of ASA and NCT in this invention;

[0058] Figure 2 This is a diagram of the original single-crystal unit cell structure of ASA and NCT in this invention;

[0059] Figure 3 The diagram shows the ASA-NCT eutectic model of this invention, which includes (a) a dimer, (b) a unit cell, and (c) a three-dimensional periodic unit cell structure.

[0060] Figure 4 A schematic diagram of the interaction coloring rules for IRI analysis;

[0061] Figure 5 PXRD powder diffraction patterns for ASA, NCT, physical mixtures, and ASA-NCT eutectic;

[0062] Figure 6 Terahertz time-domain spectra of ASA, NCT, physical mixtures, and ASA-NCT eutectic;

[0063] Figure 7 Comparison of experimental spectra of monomers and eutectic with DFT theoretical simulation spectra: (a) ASA, (b) NCT, (c) ASA-NCT eutectic;

[0064] Figure 8 This is a schematic diagram of the molecular vibrational modes corresponding to the characteristic absorption peaks of the ASA-NCT eutectic in this invention;

[0065] Figure 9 Contour lines and scatter plots for IRI analysis of ASA molecules;

[0066] Figure 10 Contour lines and scatter plots for NCT molecular IRI analysis;

[0067] Figure 11Contour lines and scatter plots for ASA-NCT eutectic IRI analysis;

[0068] Figure 12 A schematic diagram showing the coloring of hydrogen bonds and dispersive interactions of atoms in the ASA system;

[0069] Figure 13 A schematic diagram showing the coloring of hydrogen-bonded and dispersive interaction atoms in the NCT system;

[0070] Figure 14 A schematic diagram showing the coloring of hydrogen bond atoms in the ASA-NCT eutectic;

[0071] Figure 15 This is a schematic diagram of atomic coloring for the eutectic dispersion interaction of ASA-NCT.

Claims

1. An aspirin-nicotinamide drug cocrystal, characterized in that, The eutectic is composed of aspirin (ASA) and nicotinamide (NCT), with a molar ratio of aspirin to nicotinamide of 1:

1. The powder X-ray diffraction pattern of the eutectic exhibits characteristic diffraction peaks at 2θ = 9.21°, 13.80°, 17.18°, and 28.74°. The terahertz time-domain spectrum of the eutectic exhibits unique characteristic absorption peaks at 0.91 THz, 1.51 THz, and 1.79 THz; the equivalent aspirin solubility at 20℃ is 17.6 times higher than that of pure aspirin.

2. The method for preparing the aspirin-nicotinamide drug cocrystal according to claim 1, characterized in that, It includes the following steps: S1: Take aspirin and nicotinamide raw material powders in a molar ratio of 1:1, with a raw material purity ≥98%; S2: Manually premix for 5 minutes under dry, low-humidity glove box conditions; S3: Grind for 2 hours at 300 r / min using a planetary ball mill; S4: Take out the grinding product, seal it and store it in a desiccator to obtain aspirin-nicotinamide drug eutectic powder.

3. The preparation method according to claim 2, characterized in that, Maintain a low humidity environment throughout the process to prevent aspirin from hydrolyzing.

4. A comprehensive characterization method for the aspirin-nicotinamide drug cocrystal as described in claim 1, characterized in that, It consists of two parts: experimental phase characterization and theoretical calculation analysis; Experimental phase characterization: Powder X-ray diffraction (PXRD) and terahertz time-domain spectroscopy (THz-TDS) in the 0.4-2.0 THz band were used to compare the monomer and physical mixture samples. The formation of the eutectic phase was determined based on the specific diffraction peaks and specific terahertz absorption peaks. Theoretical calculation analysis: A 1:1 aspirin-nicotinamide co-crystal unit cell model was constructed, and geometric optimization and spectral simulation were carried out using the DFT-D3 method; the IRI interaction region indicator was used to perform visual qualitative analysis of weak intermolecular interactions; the EDA-FF energy decomposition method was used to quantitatively separate the interactions; the PED potential energy distribution decomposition was used to complete the assignment of vibrational modes of terahertz characteristic absorption peaks, and the microscopic driving force for co-crystal formation was analyzed.

5. The comprehensive characterization method according to claim 4, characterized in that, The DFT calculations were performed using the B3LYP-D3 functional and the 6-311G** basis set.

6. A pharmaceutical composition, characterized in that, It comprises the aspirin-nicotinamide drug cocrystal of claim 1 and pharmaceutically acceptable excipients.